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Abstract
Background: Around 25% of prisoners meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD).
Because ADHD is associated with increased recidivism and other functional and behavioural problems, appropriate
diagnosis and treatment can be a critical intervention to improve outcomes. While ADHD is a treatable condition,
best managed by a combination of medication and psychological treatments, among individuals in the criminal
justice system ADHD remains both mis- and under-diagnosed and consequently inadequately treated. We aimed to
identify barriers within the prison system that prevent appropriate intervention, and provide a practical approach to
identify and treat incarcerated offenders with ADHD.
Methods: The United Kingdom ADHD Partnership hosted a consensus meeting to discuss practical interventions
for youth (< 18 years) and adult (≥18 years) offenders with ADHD. Experts at the meeting addressed prisoners’ needs
for effective identification, treatment, and multiagency liaison, and considered the requirement of different approaches
based on age or gender.
Results: The authors developed a consensus statement that offers practical advice to anyone working with prison
populations. We identified specific barriers within the prison and criminal justice system such as the lack of adequate:
staff and offender awareness of ADHD symptoms and treatments; trained mental health staff; use of appropriate
screening and diagnostic tools; appropriate multimodal interventions; care management; supportive services;
multiagency liaison; and preparation for prison release. Through discussion, a consensus was reached regarding
prisoners’ needs, effective identification, treatment and multiagency liaison and considered how this may differ
for age and gender.
Conclusions: This practical approach based upon expert consensus will inform effective identification and treatment
of offenders with ADHD. Appropriate intervention is expected to have a positive impact on the offender and society
and lead to increased productivity, decreased resource utilization, and most importantly reduced rates of re-offending.
Research is still needed, however, to identify optimal clinical operating models and to monitor their implementation
and measure their success. Furthermore, government support will likely be required to effect change in criminal justice
and mental health service policies.
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Background
Effective identification and treatment of offenders with
attention-deficit/hyperactivity disorder (ADHD) in the
prison population is likely to have a positive impact on
the offender and society. ADHD is associated with early
age criminality [1], a high rate of recidivism [2], and a
two to three-fold increased risk of later arrest, convic-
tion, and imprisonment [1]. While ADHD is a treatable
condition best managed by a combination of appropriate
medication and psychological treatments [3], among in-
dividuals in the criminal justice system ADHD remains
both mis- and under-diagnosed [4–6] and consequently
inadequately treated.
ADHD is characterized by symptoms of pervasive and
impairing inattention and/or hyperactivity and impulsiv-
ity [7] that starts during childhood or early adolescence
and persists in around half of individuals into adulthood
[8], where it is associated with significant personal, so-
cial, and occupational problems [9]. Compared with in-
mates without ADHD, inmates with ADHD symptoms
demonstrate a high frequency and severity of functional
impairment that worsen in proportion to the severity of
their ADHD symptoms [4, 5].
Worldwide prevalence rates estimate that 5.3% of chil-
dren and 2.5% of adults meet diagnotic criteria for ADHD
[10, 11]. Meta-analyses of 42 prisons, based on inter-
national data derived from symptom-based clinical diagnos-
tic interviews, indicated that 25.5% of the prison population
overall met diagnostic criteria for ADHD [12]. Compared
with the worldwide prevalance of ADHD, this is a five-fold
increase among youth prisoners (< 18 years) and a ten-fold
increase among adult prisoners (≥18 years) [12].
Among incarcerated adults with ADHD, there is an in-
creased risk of associated coexisting psychopathology [13]
that often confounds and influences treatment options.
Given the high risk of co-morbid mood disorders among
youth and adult offenders with ADHD [5], paired with
their high risk of self-harm or suicide in the first weeks of
prison reception [14], it is imperative to identify prisoners
at risk of aggression, violence, self-harm, and suicide who
might benefit from treatment for ADHD. It is also import-
ant to identify prisoners with ADHD with co-morbid
substance use disorders, so that they may undergo detoxi-
fication treatment in prison before receiving treatment for
ADHD. Adults with undiagnosed ADHD treated for other
mental health disorders such as major depression, anxiety,
bipolar, and/or personality disorders, have poor clinical
and functional outcomes if ADHD goes untreated [5].
When appropriately diagnosed and treated for ADHD,
there is likely improved ADHD symptom control, emo-
tional lability, and overall functioning. Furthermore, out-
come studies indicate reduced rates of transport
accidents, criminality, and suicidal behaviour during pe-
riods of treatment for ADHD [5, 15–17].
Although there is a large evidence base for ADHD
treatments for individuals in the community, similar evi-
dence is limited for those in the prison population. A lit-
erature review of non-offender populations with ADHD
reported that the combination of pharmacological and
non-pharmacological treatment was most consistently
associated with improved long-term outcomes and large
effect sizes [3]. An Icelandic study of non-offender
adults with ADHD reported that those who received the
multi-modal treatment of ADHD medication plus the
ADHD version of Reasoning and Rehabilitation 2 for
Youths and Adults (R&R2ADHD) [18], experienced a
significant reduction in ADHD and co-morbid symp-
toms and demonstrated improved functional outcomes
[19–21]. A Swedish national database study of released
prisoners reported that rates of violent reoffending were
reduced by 42% during periods when they were receiving
antipsychotics, psychostimulants, and/or drugs for ad-
dictive disorders, compared to periods in which they
were not receiving medication [22]. Another Swedish
database study reported that among those treated for
ADHD, criminal conviction rates were reduced by 32%
in men and 41% in women over a 3 year period [23].
As of October 2015 the World Prison Population List
conservatively estimated that up to 11 million people
were held in penal institutions throughout the world
[24]. With around a quarter of prisoners worldwide
meeting diagnostic criteria for ADHD, we estimate that
2.8 million prisoners have ADHD.
Given the large population of prisoners with ADHD
combined with their increased risk of recidivism, appro-
priate intervention is crucial. By expanding upon the con-
sensus of the United Kingdom Adult ADHD network
(UKAAN) on the identification and management of of-
fenders with ADHD [6], we aimed to identify existing bar-
riers within the prison system that prevent appropriate
intervention, and provide a practical approach to effect-
ively identify and treat incarcerated offenders with ADHD.
Methods
The United Kingdom ADHD Partnership (UKAP;
www.UKADHD.com) hosted a meeting in November
2016, where researchers, prison staff, clinicians, and pa-
tient representatives with expertise in offender mental
health and ADHD, convened to discuss identification
and treatment of youth and adult offenders with ADHD
in the prison population. Each author attended the
meeting. The authors represent a multidisciplinary
group including both prescribing and non-prescribing
clinical and academic experts, with extensive experience
working with individuals with ADHD, including pris-
oners (for further details see Authors’ Information sub-
section of the Declarations section). The meeting
included presentations with electronic slides,
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discussions, and group work. Presentations and discus-
sions were recorded and later transcribed.
The meeting commenced with four presentations:
 The Facts: What We Know from Empirical Data
 Needs, Problems, and Obstacles when Assessing and
Treating ADHD in a Young Offender Institution
 Needs, Problems, and Obstacles when Assessing and
Treating ADHD in an Adult Prison
 Beyond the Gates: Needs, Multiagency Liaison, and
the Care Pathway
Following the presentations, all attendees separated into
three small groups. Each group was tasked with providing
practical solutions relevant to their assigned topic. The
methodological orientation that underpinned the focus of
the discussion groups was phenomenological, using the
empirical research base and their clinical experience.
Group leaders facilitated the small-group discussions
while scribes took notes and summarized their groups’ an-
swers to the following topical questions:
1. Identification and Assessment
 How do we identify ADHD among youth
offenders? Among adult offenders? What are the
screening tools?
 What should trigger additional assessments and
referrals? And to whom?
 What should these assessments involve for youth
offenders? For adult offenders?
 Are there significant gender differences to take
into account?
2. Interventions and Treatment
 What are the appropriate pharmacological
treatments for youth offenders? For adult
offenders?
 What are the appropriate non-pharmacological
treatments for youth offenders? For adult
offenders?
 What is the evidence base for these treatments?
 Are there significant gender differences to take
into account?
3. Care Management and Multiagency Liaison
 What agencies need to be involved in developing
a care plan for youth offenders? For adult
offenders?
 What might trigger multiagency liaison?
 What should be considered when providing
support to families and carers?
 What kind of educational, behavioural, and/or
socialization support should be established to
meet the needs of this population?
 Are there significant gender differences to take
into account?
Following the small-group work, all attendees
re-assembled together. The leaders then presented their
findings in a feedback session to all the attendees for an-
other round of discussion and debate, until a final con-
sensus was reached. The medical writer consolidated the
meeting transcription, electronic slide presentations, and
small-group notes into the manuscript. Lastly, the meet-
ing transcription and manuscript were circulated to all
authors for review to ensure agreement. The consensus
reported here reflects the views of the authors based on
their experience and is supported by published research;
and aimed to provide practical guidance to health care
professionals working with prisoners with ADHD.
Results
The authors successfully came to a consensus on a prac-
tical approach to identify and treat prisoners with
ADHD. While our approach draws primarily from our
experiences in the UK, we believe it can be easily
adapted for use in other countries.
Identification and assessment
The identification and accurate diagnosis (including con-
firmation of a previous diagnosis) of ADHD among pris-
oners is a process reliant on the availability of medical
records, mental health clinicians trained to conduct
interview assessments for ADHD, prison staff trained to
recognise potential patients with ADHD, and suitable
screening and diagnostic instruments. It will be neces-
sary to use identification and assessment tools that are
specific to youth or adult offenders. According to best
practice all new prisoners should receive an initial recep-
tion screen for mental health problems, including
ADHD, followed by a comprehensive second screen
shortly after their reception screen [25, 26].
Identifying prisoners with ADHD
While some prisoners present with a history of ADHD di-
agnosed during childhood, others present with no history
of ADHD, or alternative diagnoses such as specific learn-
ing difficulties (dyslexia, dyspraxia) or conduct problems.
It is therefore important to review the medical history and
confirm the presence of other common mental health and
neurodevelopmental disorders that may overlap with
ADHD — highlighting the need for a careful diagnostic
assessment. In our experience, many offenders who had a
prior diagnosis of ADHD were untreated or failed to ad-
here to their treatment programme. In making a new
diagnosis, there are specific indicators among the prison
population that, in our experience, suggest the presence of
ADHD and are as follows:
 Symptoms of inattention, which are often missed
among offenders of both genders
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 Symptoms of impulsivity, emotional dysregulation,
and poor self-control, which are especially important
to recognize as the prisoner may be at risk of
aggression and violence towards others, or self-harm
and suicide
 A history of educational failure, school expulsion,
inability to work, driving offences, and impulsive
aggression, and/or
 A history of chronic mental health problems or a
history of failed treatment programmes for conditions
such as mood disorders, anxiety, depression,
post-traumatic stress disorder, emotional instability,
self-harm, and/or borderline personality disorder.
We have observed that assessors commonly view hyper-
activity as a ‘male’ ADHD symptom and inattention as a
‘female’ ADHD symptom. This bias may interfere with
making an accurate diagnosis of ADHD in males who lack
overt hyperactivity and in females who display hyperactive
behaviour. Diagnosing ADHD in offenders can be add-
itionally challenging because it is often complicated by the
high frequency of co-occurring conditions. In addition to
common disorders seen in the prison population such as
anxiety, depression, post-traumatic stress disorders, sub-
stance abuse and self-harm, borderline personality disor-
ders are commonly found among female offenders [27,
28], and conduct and antisocial personality disorder
among males; all potentially masking the diagnosis of
ADHD. Consequently, further training is often required to
support the accurate identification of ADHD symptoms
and distinguish these from other disorders.
Prison staff ADHD awareness training
Currently there is very limited training about ADHD for
prison staff. Raising awareness of ADHD was however
considered to be essential by the consensus group.
ADHD awareness training is likely to reshape miscon-
ceptions or stereotypes of ADHD and may improve the
outcomes of offenders with ADHD within the criminal
justice system. It is important to understand that al-
though ADHD is a pervasive condition that persists into
adulthood in around half of cases, it is treatable at all
ages. Prison officers, clinicians, educators, therapists,
and mentors therefore should be trained to recognize
the signs and symptoms of ADHD and further educated
on available treatments and expected outcomes.
ADHD awareness training should ideally raise the visi-
bility of the disorder. Increased understanding and rec-
ognition of ADHD will likely help prison staff to better
manage offenders with ADHD presenting with difficult
behaviours that were previously unattributed to the dis-
order [2]. While any member of prison staff can refer a
prisoner for a mental health assessment at any time,
referrals are dependent on their vigilance and ability to
make appropriate observations.
Delivery of ADHD awareness training (alongside train-
ing for mental health more generally) in the prison set-
ting may have logistical challenges, such as lockdown
requirements to allow staff to attend workshops.
However, training in mental health issues, including
ADHD, is essential for this high-risk population and
needs to be addressed at each institution.
Screening for youth offenders
Primary screen
As is the case for many prisons, all youth offenders are sub-
ject to a reception screen upon admission. Screening pref-
erences and practices vary greatly between institutions
world-wide, and while no evident gold standard method ex-
ists, healthcare standards offer guidance for best practices
for youth in secure settings [29]. Nurses with mental health
experience usually administer the primary screen to assess
the overall physical and mental health of the offenders.
The National Health Service England (NHSE) mandates
using the comprehensive health assessment tool (CHAT) in
youth offender institutions throughout England and Wales.
Because of the NHSE requirements, we recommend using
the CHAT as the primary screen in all youth offender insti-
tutions. The CHAT is a validated semi-structured interview
designed to screen for health issues among all young of-
fenders admitted to a secure facility [30]. CHAT is divided
into four sections covering: physical health, mental health,
substance abuse, and neurodisability. It is available in elec-
tronic format; however, the mental health section takes ap-
proximately one hour to complete.
Questions pertaining to ADHD symptoms are in-
cluded in the mental health section of the CHAT, but
because they focus on externalizing rather than internal-
izing symptoms the assessors will need to take extra care
in considering all symptoms, including the inattention
symptoms of ADHD. While we acknowledge the poor
specificity of CHAT, it is a sensitive tool for detecting
mental health problems that include ADHD. It is there-
fore important to emphasize that the CHAT should be
used as a primary screen to flag potential mental health
issues before going on to more detailed assessments.
If any chronic or serious mental health issue is sus-
pected, then the offender should be referred for a second-
ary screen involving a more comprehensive assessment by
a multidisciplinary mental health team including nurses,
psychologists, and psychiatrists who are specially trained
to recognize ADHD as well as other mental health condi-
tions commonly seen in young offenders.
Secondary screen and clinical diagnosis
At the time of clinical assessment, we recommend that a
trained clinician administer a standard validated rating
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scale such as the Swanson, Nolan, and Pelham teacher
and parent rating scale (SNAP-IV) [31] and/or the
Conners’ comprehensive behaviour rating scale
(Conners’ CBRS) [32] to assist in making the diagnosis
and to gather necessary collateral information. A diagno-
sis of ADHD usually requires supporting evidence from
teacher, therapist, employer, or parent reports. In cases
where screens indicate a possible ADHD diagnosis, we
recommend that clinicians always conduct a full diag-
nostic interview for ADHD, as well as carefully assess
for commonly occurring co-morbid conditions such as
drug abuse, personality disorders, emotional problems,
and learning difficulties. The ADHD Child Evaluation
(ACE) [33] is one such tool used for assessing ADHD
symptoms, possible co-morbid problems, and associated
impairments. The ACE is a semi-structured diagnostic
interview providing either DSM-5 or ICD-10 [7] criteria
and is available in 19 languages free of charge in paper
form. Those who are symptomatic on screening, but
have a confirmed pre-existing diagnosis of ADHD may
not require a diagnostic interview. This will largely de-
pend on how long ago the diagnosis was made and is a
matter of clinical judgment.
Screening for adult offenders
Primary screen
In adult prisons offenders are subject to a reception
screen upon admission, to review their overall physical
and mental health. In most institutions, however, the
mental health section of the primary screen for adult of-
fenders does not include questions pertaining to ADHD
symptoms. For example, the screening tool Health &
Wellbeing Needs Assessment Toolkit (HWBNA) pub-
lished by the Public Health England Health & Justice
Team, to be used in all 118 adult English Prisons, has no
mention of ADHD. Screening preferences and practices
vary greatly between adult institutions world-wide and
while no evident gold standard method exists, several
valid tools are available [25].
Some prisons have adopted the short screening version
of the Adult ADHD Self Rating Scale (ASRS), [34] yet in
our experience, because of the wording of the questions,
this is less suitable for prison populations. We identify
this as problematic and therefore suggest using the brief
version of the Barkley Adult ADHD rating scale
(B-BAARS) as part of the primary mental health screen.
The B-BAARS is a short, six-item screen with excellent
specificity and sensitivity for predicting a diagnosis of
ADHD in the offender population, and is available free
of charge [33, 35].
Ideally, nurses with mental health experience should
administer the primary screen in adult institutions as
this increases the validity of the screens by ensuring
questions are understood and properly rated by the
offenders [36]; however, this is usually not the case.
Nurses in adult prisons and police stations tend to be
physical health nurses without mental health experience.
This may cause difficulties with identifying ADHD
symptoms, as well as other mental health disorders, in
the primary screen and may prevent triggering a second-
ary screen among adult offenders. Because of this, we
recommend employing nurses with mental health ex-
perience throughout the criminal justice system offender
pathway to adequately assess the overall physical and
mental health of adult offenders.
If any co-morbid mental health disorder is suspected, then
the offender should be referred for a secondary screen in-
volving a more comprehensive assessment by a multidiscip-
linary mental health team including nurses, psychologists,
and psychiatrists who are specially trained to recognize
ADHD as well as other adult mental health conditions.
Secondary screen and clinical diagnosis
In cases where a B-BAARS score or results from another
screen indicate a likely ADHD diagnosis, we recommend
a clinician trained in the assessment of ADHD conduct
a full diagnostic interview. This may include the full
18-item version of the BAARS to ascertain the severity
of ADHD. Whenever possible, the interview should be
supported by collateral reports (e.g., parent, therapist,
and previous medical history) to gain a comprehensive
description of their symptoms and impairments across
the lifespan. While informant reports are not always re-
quired, they can be particularly useful as offenders with
ADHD often have very poor recollections of their child-
hood behaviour and tend to minimise impairments aris-
ing from ADHD. Extra care is needed when evaluating
all of the offenders’ symptoms to avoid focusing only on
externalising behaviours.
We have identified three comprehensive semi-structured
diagnostic interview tools that are suitable for adult prison
populations: the Conners’ Adult ADHD Diagnostic
Interview for DSM-IV (CAADID) [37], the Diagnostic
Interview for ADHD in adults (DIVA-2) [38, 39], and the
ACE+ (ACE for adults) [40]. While the CAADID and
DIVA-2 are the more established methods, the ACE+ has
an advantage because it includes a section that considers
coexisting conditions and whether they are co-morbid or
reflect a differential diagnosis. For this reason, the ACE+
may be preferred when establishing the diagnosis of ADHD
in the presence of co-morbid disorders. The DIVA-2 is
widely used throughout Europe and should be used in con-
junction with a systematic assessment of co-morbidity be-
cause it does not include a prompt to evaluate the presence
of common co-morbid conditions. Both the ACE+ and
DIVA-2 are available in many languages other than English
and are free of charge in paper form.
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Each of these interviews provides age-appropriate ex-
amples of each of the ADHD symptoms that can be ap-
plied when evaluating adults. Relevant descriptions of
adult ADHD symptoms include: internal restlessness; ex-
cessive mind wandering that interferes with tasks such
as reading, writing and listening to TV or conversations;
getting bored quickly then losing ability to focus; and
feelings of irritability and impatience when waiting in
queues. Clinicians also need to be aware that symptoms
of emotional dysregulation such as frequent inappropri-
ate levels of irritability, frustration, and anger (while not
part of the formal diagnostic criteria) can be used to
support the diagnosis [7].
While continuous performance tests (CPT) perform
reasonably well at discriminating between people with
ADHD from non-psychiatric controls, and may contrib-
ute to the diagnostic assessment, they are far less able to
discriminate ADHD from other common psychiatric dis-
orders seen in prison populations [38]. Given these val-
idity issues and the logistical problems of bringing
information technology equipment into prisons, we can-
not recommend their use in prison populations.
Interventions and treatment
Providing appropriate pharmacological and non-pharmacological
interventions in prison populations is a process reliant
on prison staff and offender self-awareness of ADHD
symptoms and treatments, the availability of trained
mental health clinicians, and the administration of spe-
cifically targeted multimodal treatments. Although fe-
male offenders often present with a more complex
profile due to pregnancy, motherhood, and high levels
of co-morbidity [13], all pharmacological and
non-pharmacological treatments can be administered
irrespective of age and gender. During pregnancy,
ADHD pharmacological treatments can be used, but
should be restricted to cases where treatment is re-
quired to reduce significant distress and behavioural
problems, where the potential risks of no treatment
outweigh risks of treatment [41].
It will be necessary to educate offenders on the efficacy
of multimodal treatments and expected outcomes and to
obtain informed consent for permission to treat. Following
a new or confirmed previous diagnosis of ADHD and a
careful evaluation of possible co-morbid conditions, we
recommended the following multi-modal treatment for
incarcerated offenders, as summarized in Fig. 1.
We have observed that staff support in pharmacological
treatment and involvement in psychological treatment
programmes has a positive and direct impact on offender
adherence to and engagement in the prescribed treatment
plan. Staff lack of knowledge about ADHD can interfere
with medication administration and offender engagement
in psychological treatment programmes. Conversely, staff
awareness of ADHD symptoms, and observation of posi-
tive treatment effects, usually increases engagement with
and support for the treatment process, and makes it much
more likely they become involved in the delivery of of-
fenders’ psychological treatments.
According to principle and law, punishment for criminal
offence is the loss of liberty, and prisoners’ human rights
are fully protected unless restrictions are unavoidably and
demonstrably ‘necessitated by the fact of incarceration’
[42]. The Mandela Rules expressly state the fundamental
prohibitions on torture and inhumane treatment, and
emphasize that imprisonment is itself the punishment and
should not carry additional ‘pains’ [42]. Solitary confine-
ment is arguably considered to be an additional ‘pain’, with
especially significant adverse effects for people with ser-
ious mental illness; it has negative psychological conse-
quences and restricts the inmates access to mental health
services [43, 44]. Although ADHD is often un-recognized
as a serious mental illness, we contend that severe cases
should be recognized as such, and particularly when
ADHD related behaviours are severe enough to lead to
isolation of sentenced prisoners. We have observed that
solitary confinement exacerbates prisoners’ ADHD symp-
toms [45], and recommend increasing efforts to ensure
that offenders with ADHD are prevented from receiving
this punishment. The same argument can be applied to
severe cases of other mental health disorders, so it not
unique to ADHD. This may require prisons to reduce the
use of solitary confinement for all prisoners and to ensure
that it is only used as a last resort, for short periods of
time to manage acute situations, and never as a
punishment.
Given the high prevalence of neurodevelopmental dis-
orders (traumatic brain injury, communication disorders,
dyslexia, learning disabilities, autistic spectrum disorder,
and ADHD) among young offenders [46], it is especially
important to staff the prisons appropriately with educa-
tional psychologists and speech/language therapists to
meet their needs adequately. Currently, prisoners with
these needs are either inadequately supported or receive
these necessary services only upon release.
Pharmacological treatments for offenders
Treatment with ADHD medication is effective in reducing
symptoms of inattention, hyperactivity, and impulsiveness
[47] and is also reported to be associated with a significant
reduction in violent reoffending (around 42%) on release
from prison [22] and similarly in criminal convictions
[23]. By reducing their ADHD symptoms, the offender is
likely better equipped to engage in and benefit from psy-
chological, educational, and occupational interventions. It
is important for offenders and prison staff to understand
that, although ADHD medication reduces ADHD
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symptoms, it does not cure the disorder, and concomitant
non-pharmacological treatments are nearly always neces-
sary to help the offender manage ADHD related problems
and improve their behaviour.
Given the lack of sufficient high quality evidence from
randomized-control trials for treatment among pris-
oners, it is important to emphasize that clinicians
trained in the diagnosis and treatment of ADHD should
administer ADHD medications, to carefully asses for
risks of abuse potential and possible risks of exacerbat-
ing other co-morbid conditions. Medication can be ad-
ministered to all offenders irrespective of age and
gender, but type and dosage should be made on an indi-
vidual basis, especially in the case of pregnancy.
With respect to psychoeducation, the offender needs
to be educated on the benefits and side effects of
pharmacological treatment and the implications of
remaining untreated or discontinuing treatment. This
education is not only necessary in obtaining informed
consent to treat, but is important in engaging them in
their own treatment. Such engagement will encourage
offenders to take an active role in their treatment and
can cause them to perceive some control over their situ-
ation, which can have an empowering effect. Offenders
need to be given adequate opportunities to provide feed-
back on the medication’s effect and to titrate for thera-
peutic doses. Support during the early stage of treatment
is critical in helping offenders take full advantage of the
Fig. 1 Multimodal Treatment for Incarcerated Offenders with ADHD
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reductions in ADHD symptoms and in helping manage
the medication's side effects.
We recommend prescribing stimulant medications
first line because these have a quicker response than
non-stimulants and a greater average effect size. Drugs
with a high risk of abuse, such as immediate release
preparations of methylphenidate (MPH) and dexamfeta-
mine (DEX), should be avoided in prison populations
due to the potential for abuse. Injected or insufflated
(snorted) MPH and DEX cause a rapid release of dopa-
mine that can give the user a ‘high’. This does not occur,
however, when these medications are taken orally. The
oral administration of therapeutic doses of MPH or DEX
is therefore essential in reducing the abuse potential of
stimulant medications [48].
We recommend prescribing long acting or modified re-
lease preparations of methylphenidate (MR MPH) that are
difficult to take in any other way than by mouth (e.g. Con-
certa XL). Lisdexamfetamine (Elvanse) is a long acting
preparation that has a unique advantage, because even if
injected, the active drug is released slowly at a similar rate
in to the brain as when taken by mouth. These extended
release formulations are usually taken in the morning and
give active control of symptoms for 8–14 h in most cases.
MR MPH, lisdexamfetamine, along with all other stim-
ulants, are controlled substances and thus subject to
strict dispensary logistics that often interfere with treat-
ment compliance and efficacy. Restrictions on move-
ments within the prison can limit the regular and timely
administration of stimulant (and other) medications. In
some cases, staff are needed to escort prisoners to the
healthcare unit to receive medication, although in most
cases prisoners can take themselves to a dispensary, or
receive medication from a wheeled cart. Escorting not
only over burdens the staff, but stigmatizes the offender
and further complicates adherence. Although stimulants
are controlled substances, they can usually be dispensed
in the same manner as other non-stimulant medications
that are not kept in possession, which improves adher-
ence. The practice of dispensing drugs varies by prison,
but non-stimulants are easier to dispense as there are
less procedures for nursing staff to follow.
Preliminary results of a pilot study of Concerta XL in
adult offenders with ADHD (CIAO) indicated a signifi-
cant reduction in total critical incidents (assaults, fights,
property damage, self-harm, drug use, and acts of dis-
obedience) among prisoners in the UK who were treated
for 12 weeks. In relation to dose, over half of the pris-
oners took 18-36 mg and only 4% took the maximum
dose of 90 mg, indicating a lack of drug seeking behav-
iour with regard to Concerta XL in this population. This
was in line with our clinical experience that suggests
greater abuse potential for sedative antidepressants and
antipsychotics than stimulants within the prison
population. The findings from this study were success-
fully used to secure further funding the National Insti-
tute of Health Research (NIHR) for an ongoing
randomised controlled trial in 200 young adult offenders
following a similar study design. We anticipate that the
reports from these studies will inform optimal medical
treatment of ADHD in prisons and raise public aware-
ness for the need for effective treatment of offenders
with ADHD (unpublished report for pilot study available
from PA).
In alignment with national guidelines [49], we recom-
mend prescribing non-stimulants, such as atomoxetine in
adolescents under 18 and adults, and/or long-acting guan-
facine in adolescents under 18: when stimulants do not
adequately treat symptoms or cause adverse effects, when
a sustained 24-h effect is required, or there is clear drug
seeking behaviour for stimulant medications (a rare event
in our experience). In adults there is no data for the use of
guanfacine, so atomoxetine is the non-stimulant of choice.
Non-stimulants are easy to administer as they are not a
controlled substance and would therefore bypass dispens-
ary logistics and potentially improve treatment compli-
ance. Although atomoxetine and long-acting guanfacine
take several weeks to reach optimal effect, they have a sig-
nificantly longer effect on symptom control over a 24-h
period and can maintain their effect when individual doses
are missed. They are particularly useful for patients who
have a rapid return of severe ADHD symptoms once
stimulant effects wear off during the day. Additionally,
non-stimulants are the medication of choice for patients
with a previous history of stimulant abuse.
Pharmacological treatments for offenders with co-morbid
conditions
In the presence of co-morbid anxiety, autism spectrum
disorder (ASD), aggressive behaviour, or mild affective
symptoms, ADHD should usually be treated first,
followed by a careful evaluation of the medication’s ef-
fect on the co-morbid symptoms. While adults with
ADHD are reported to misuse drugs [50, 51], detoxifica-
tion is provided by prison mental health services, and
despite reports in the media about drug abuse in prison,
there is no longer regular access to major drugs of
abuse. Substance abuse is stabilised and under control in
most cases in prison settings, so that diagnostic assess-
ments and treatment for ADHD can proceed.
Symptoms commonly shared between ADHD and
co-morbid disorders may be better managed with pharma-
cological treatments for ADHD rather than with pharma-
cological treatments for the co-morbid disorders
themselves. For example, irritability and low mood symp-
toms secondary to ADHD are alleviated more effectively
by ADHD medication than with antidepressants or anti-
psychotics. Similarly, we have observed that conditions
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such as post-traumatic stress disorder and borderline
personality disorder sometimes improve following treat-
ment of concurrent ADHD. Subsequent treatments for
co-morbid disorders may be required and can be added
one at a time to discriminate their effects. Conversely, in
the presence of psychosis, bipolar disorder, and/or a clear
depressive episode, ADHD should not be treated first.
Care should be taken, however, to avoid mistaking the
ADHD symptoms of emotional instability for the episodic
mood changes of bipolar disorder or the chronic symp-
toms of a personality disorder.
In the case of co-morbid anxiety disorder, pharmaco-
logical treatment for the anxiety can be added if the
stimulant exacerbates the anxiety. Alternatively, the stimu-
lant can be discontinued and replaced by atomoxetine. In
the case of co-morbid symptoms of aggressive behaviours,
a low dose of quetiapine or risperidone may be added if
the symptoms are not adequately treated by stimulants or
atomoxetine. While high doses of quetiapine are sedative
and are used to treat psychosis, low doses have a mildly
sedative effect that can help reduce irritability and emo-
tional liability associated with ADHD.
Unfortunately, there are insufficient studies of the
treatment of ADHD in co-morbid cases, and offenders pre-
senting with complex mix of co-morbidities. Our recom-
mendations are therefore based on the experience of the
authors, which are aligned with recommendations from
guideline groups such as NICE [49]. In our experience,
while a significant proportion of offenders with co-morbid
conditions respond positively to the treatment of ADHD,
there are cases that show limited or no response. Severe ad-
verse effects on co-morbid conditions, including risk of
psychosis, however appear to be extremely rare. The most
common complaint is appetite loss. Overall, we conclude
that while further work is needed to identify the predictors
of good and poor response among patients with co-morbid
conditions, the potential benefits of treatment outweigh the
potential risks. The risks are minimised by careful monitor-
ing of treatment effects during the titration phase of drug
administration. In accordance with published guidelines
[49], when titrating stimulants we recommend weekly as-
sessments for 4–5 weeks, and less often for non-stimulants
.
Non-pharmacological treatments for offenders
Non-pharmacological treatments in the prison setting
consist of psychological, educational, and occupational
treatment programmes. These interventions should aim
to: facilitate changes in life-long patterns of poor behav-
ioural control, increase life satisfaction, build useful
skills, and help the offender plan for civilian life after re-
lease. Mentorship programmes embedded in the treat-
ment plan are likely to be additionally beneficial.
Pharmacological treatment of ADHD symptoms will
enable offenders who respond to such treatments to bet-
ter engage in and benefit from non-pharmacological in-
terventions in this setting. It is important to emphasize
that, although ADHD medication can improve symp-
toms, concomitant non-pharmacological treatments are
nearly always necessary to help the offender manage
ADHD related problems and improve their behaviour.
Offender psychoeducation
There is a need to change common misconceptions and
stereotypes about ADHD symptoms and treatments.
Young people and adults find it helpful to understand
that ADHD is a neurobiological disorder evident early in
life and distinct from other behavioural problems. It is
especially important for offenders to understand that al-
though ADHD is pervasive, treatment may help improve
self-control and level of function. In our experience pris-
oners value improvements in attention span and reduced
levels of physical restlessness and emotional impulsivity
that would enable them to benefit from education. Men-
tal health professionals working with prisoners with
ADHD should provide a clear explanation of ADHD
symptoms, treatments, and expected outcomes, and
educate the offender on the potential risks of remaining
untreated or discontinuing treatment. Additionally, we
recommend giving offenders an easy-to-read pamphlet
that briefly highlights some facts about ADHD.
Offender psychoeducation is an integral part of inter-
vention that should be initiated during imprisonment to
increase its efficacy and to avoid overwhelming the of-
fender upon release. We commonly observe that offenders
are not adequately educated about their condition and
take a passive role in their treatment plan. Furthermore,
we have observed that an offender’s increased understand-
ing of their condition helps them to engage in their
pharmacologic and psychological treatment programmes
and increase their sense of self-empowerment.
Psychological treatment programmes
Many UK prisons implement offending behaviour pro-
grammes that focus on addressing the risk of future
offending behaviour, but these do not provide treatment
for clinical conditions for offenders with ADHD. We
recommend implementing a neurocognitive intervention
that addresses offending behaviour and ADHD related
and other behavioural co-morbid executive function def-
icits such as: difficulty with time-keeping, organizing,
planning, and self-regulating emotions and behaviour.
Given the logistical limitations inherent in correctional
institutions (e.g. restrictions on movement and variations
in sentencing), it is important that treatment programmes
are suitable and feasible for the prison environment.
Appropriate programmes include those that can be:
completed in a relatively short amount of time (less than
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4 months), delivered in a small group setting with about
10 to 12 inmates once or twice per week, and adminis-
tered to all offenders irrespective of age and gender.
To augment and fortify interventions we recommend
providing the offender with personal support from a men-
tor (i.e. coach or champion). Prison staff, officers, sub-
stance abuse staff, primary and secondary care clinicians,
educators, volunteers, and when appropriate even fellow
prisoners, can be trained to provide one-on-one
skill-building sessions. These one-on-one sessions
emphasize a personal approach and can help the offender
bridge lessons from the therapy room to daily life.
To the best of our knowledge the only psychological
treatment programme developed to address antisocial be-
haviour and executive functioning deficits is Reasoning
and Rehabilitation 2 ADHD (R&R2ADHD). R&R2ADHD
is a treatment programme based on cognitive behaviour
therapy designed to build pro-social competence [18] and
may be used in non-offender and prison populations. It
can be administered to all offenders irrespective of age
and gender and completed in approximately 2 months.
The programme’s short duration, comprised of 15 treat-
ment sessions deliverable up to 2 times per week, makes it
favourable to ensure completion. R&R2ADHD has an
additional advantage of being suitable for both youth and
adult offenders. Furthermore, mentorship is embedded
within the programme — whereof an assigned coach or
mentor meets one-on-one with the offender between ses-
sions to help them consolidate and apply newly learned
skills in their daily life.
While the evidence for R&R2ADHD efficacy is predom-
inantly community based with a majority of male samples
[19–21], results from a pilot trial at Her Majesty’s Prison
Youth Offender Institution (HMP/ YOI) Feltham (a level
3 youth offender institution in the UK) indicated high
rates of completion and universally positive feedback from
enrolled youth offenders. We observed that the positive
impact of R&R2ADHD on the youth offenders with
ADHD at HMP/YOI Feltham was even more significant
when prison staff were involved in the treatment
programme. Oftentimes prison staff and officers have an
established rapport with offenders, and involving them
seems to improve offender engagement in the treatment
programme. According to the 2013 London Mayor’s
Office for Policing and Crime (MOPAC) report,
R&R2ADHD was mentioned as an example of good prac-
tice and has received the full support of London prison
governors and lead staff [52].
Other psychological approaches that may be helpful in-
clude cognitive remediation therapy (CRT) [53] and dia-
lectical behavioural therapy (DBT) [54]. CRT applies
techniques historically used to treat individuals with
traumatic brain injury (e.g. deficits in planning, time man-
agement, and attention, impulse control). DBT was
developed for the treatment of borderline personality dis-
order. Ideally, psychological interventions should take an
eclectic approach drawing on these paradigms as well as
cognitive behaviour therapy (CBT). The Young-Bramham
Programme, is one such CBT intervention that can be
used for adolescents and adults with ADHD [55].
Educational and occupational treatment programmes
Children with ADHD are at an increased risk of academic
underachievement [56] and repeating an academic year
[57], therefore all prisoners should have numeracy and lit-
eracy assessments to identify academic impairments. An
appropriate individualized education plan based upon aca-
demic assessments developed by the prison education de-
partment can be additionally informed by mental health
screen results, and previous mental health and school re-
cords, pending prisoner consent to information sharing
between departments. The CHAT screening tool assesses
for learning difficulties in young people (in the neurodisa-
bility section, part 5). These results should be used in de-
veloping a young offender’s education plan, and will
consequently inform overall holistic care.
It is important that the education plan addresses gaps in
the offenders’ academic core skills, focuses on strengths,
includes ADHD support strategies, and is appropriate for
those disengaged from the education system. Education
support workers and volunteers from outside private orga-
nizations can be helpful with implementing the education
plan. While education services have information pertinent
to learning difficulties, they do not automatically liaise
with mental health services. We have observed that prob-
lems with information sharing are primary barriers that
need to be to overcome. Therefore, we recommend an ad
hoc liaison between mental health and education services
to ensure effective intervention.
Prison rules most often require that offenders complete
an academic course (related to reading and writing) before
participating in technical skill-building workshops. Be-
cause symptoms of inattention, hyperactivity, and behav-
ioural difficulties can prevent the offender from
meaningful participation in academic courses, this re-
quirement is inherently biased against them. Imposing this
requirement upon offenders with ADHD who are at risk
of disengaging from and failing the academic course may
result in extended prison time. For example, in England
and Wales, if an offender fails the Imprisonment for Pub-
lic Protection (IPP) course they are subject to an increased
prison sentence.
We recommend waiving the requirement to complete
an academic course and directing offenders towards edu-
cational and occupational programmes that suit their
strengths (e.g. creative, technical, and/or athletic skills).
Focusing on their strengths may not only reduce the
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occurrence of extended sentencing, but also the rate of of-
fenders with ADHD in solitary confinement. In cases
where solitary confinement has not been averted, we rec-
ommend shortening the period(s) of isolation and giving
the offender an activity to occupy them while confined.
Participation in technical skill-building workshops can
provide hands on experience and the opportunity to
learn occupational and technical skills useful for life dur-
ing and after prison. In our experience, maintenance
jobs throughout the prison (e.g., housekeeping, kitchen,
and garden work) that provide the opportunity to be
physically active and occupied, are highly sought after by
ADHD offenders.
In addition to acquiring technical skills, it is important
that offenders are taught necessary personal life skills to
equip them to successfully navigate civilian life after
prison and not re-offend. Given the likelihood of execu-
tive function deficits, offenders with ADHD most often
need help planning how to attain their goals. Long-term
desires and goals (e.g., health, wealth, and happiness)
need to be broken down into realistic achievable
short-term plans and goals (e.g., self-care and employ-
ment). R&R2ADHD [18] notably includes a module that
focuses on offender needs of this nature.
Care management and multiagency liaison
As for people with mental health problems or related
complex needs, offenders with ADHD require assistance
from a wide variety of supportive services and agencies.
It is important that these services are accessed and coor-
dinated during imprisonment, not only to infer maximal
benefit, but to ensure continuity of care once the pris-
oner is released. Supportive services and agencies, al-
though distinct and separate entities, will need to liaise
with each other to exchange information and help en-
sure comprehensive care. For example, education ser-
vices should automatically be contacted when an
offender with mental health issues is identified.
Care plan and care coordination
In England people having complex needs are often eli-
gible to receive a Care Programme Approach (CPA). A
CPA is a structured multidisciplinary care management
format designed to support people with severe and en-
during mental health problems. Service users are allo-
cated a care plan coordinator (e.g., community
psychiatric nurse, social worker, psychologist or psych-
iatrist) who is responsible to review, access, and coordin-
ate multiple available services on their behalf [58]. The
structure of a CPA requires that issues are clearly
addressed according to distinct domains of need
(e.g., mental health, medication, accommodation,
education, financial) and consequently clearly identifies
which agencies are responsible to fulfil those needs. While
the care plan coordinator is central to a CPA, it is import-
ant for them to encourage the service user to take an ac-
tive role in their care plan as much as possible.
A CPA is routinely implemented for high risk patients
in inpatient settings, yet less commonly in community
mental health settings. Although the National Institute
for Health and Clinical Excellence 2018 (NICE) guide-
lines [59] recommend that individuals with ADHD aged
16 and over receive a CPA, many offenders with ADHD
are not adequately identified and subsequently do not
receive an appropriate care management plan. In our ex-
perience, continual failure to properly identify offenders
with ADHD and meet their needs can lead to some indi-
viduals to persist in offending behaviours and ‘fall
through the gap’.
We recommend offenders with ADHD receive a
CPA or similar care management plan and are
assigned a care plan coordinator to oversee the plan.
We also recommend implementing a medication
management plan, which should be a core component
of the care plan. A medication management plan ad-
dresses the need for regular built-in reviews by a suit-
ably trained psychiatrist, and the need for monitoring
medication adherence, which should be a key task of
the care coordinator. When transitioning from youth
to adult or between different institutions or out of
prison, it is vital to maintain robust care coordin-
ation, continuity of care, and uninterrupted treatment
with ADHD medication; using the CPA format can be
effective in mitigating problems with service discon-
tinuity that can arise during transitions. A sample
CPA based on numerous ‘real life’ cases is provided
in the supplementary material, see Additional file 1.
Supportive services and agencies
The following people, services, and agencies may need
to be accessed and coordinated according to the of-
fenders’ individual needs:
 Parents and carers — adults responsible to provide
general support at home and, where appropriate,
give consent to treat
 Care plan coordinators — trained workers
designated as the main point of contact responsible
to develop a care plan and review, access, and
coordinate appropriate available services
 Criminal justice services including diversion services
— police, court, prison, and offender management
unit staff responsible to move offenders through the
offender pathway while safeguarding rights; an
intermediary may be required
 Mental health services, including forensic mental
health services — trained physicians, psychiatrists,
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psychologists, nurses, and therapists responsible to
provide appropriate evaluations and treatments
 Primary and secondary care physicians— paediatricians,
general practitioners, psychiatrists, and specialist
physicians responsible to provide appropriate
evaluations and treatments
 Social services — social workers responsible to
access available financial support for appropriate
healthcare, housing, and child care needs
 Educational services — teachers, therapists, nurses,
and trained volunteers, responsible to provide
appropriate evaluations and develop and implement
individualized educational plans
 Mentorship programmes — trained coaches or
champions responsible to provide one-on-one
treatment or skill-building sessions
 Addiction services — trained clinicians, officers, or
workers responsible to provide appropriate
interventions and recovery support services
 Adoption and foster care agencies — trained
workers responsible to access appropriate placements
for youth offenders or children of offenders
 Probation services — trained officers responsible to
supervise offenders and provide appropriate
interventions
 Occupational, rehabilitation, and therapeutic
services — trained workers, therapists, job coaches,
and volunteers responsible to provide and/or access
appropriate skill-building courses and employment
opportunities to help the offender regain
independence
 Immigration services — trained workers responsible
to administrate and adjudicate cases of foreign offenders
Support for female offenders
Despite women’s inclination to seek help, female of-
fenders with ADHD may be less likely to be identified
[12] and consequently less likely to receive effective sup-
port. As mentioned previously, pregnancy, responsibil-
ities of parenting, and the risk of commonly prevalent
co-morbid disorders complicate intervention and add-
itionally cause female offenders to require varied and
unique services. The immediate access of social and fos-
ter care services is crucial when an offender is pregnant
and/or has child custody issues.
Support for youth offenders
In developing a care plan for youth offenders it is import-
ant to involve parents or carers, whenever appropriate or
possible. They can be helpful in supporting the youth once
released, especially when it comes to medication compli-
ance. Additionally, parents or carers may be required to
give consent for treatment when the youth is under
18 years old, however, obtaining consent may be
problematic in some cases. When the family is a part of
the offenders’ problems or a family member is the victim,
careful consideration is required before contacting and in-
volving them. In addition to providing psychoeducation
for the offender, families need to be educated on the facts
about ADHD symptoms, treatments, and expected out-
comes. The care plan coordinator should direct families to
parent groups or other supportive organizations and re-
sources to help them meet their child’s complex needs.
The CHAT screening tool includes a care plan summary
that highlights the young person’s needs. This information
should be communicated to all professionals working with
the young person in secure care, and to parents, carers,
and care plan coordinators following release to ensure
good continuity of care.
Support for adult offenders
In developing a care plan for adult offenders it is import-
ant to encourage them to take an active role in their care
management. When adults have been in the prison system
for many years, it can be difficult to motivate them to en-
gage in intervention and supportive services. We have ob-
served that youth offender services and pathways are
generally more developed and effective than those for
adult offenders. Therefore, we recommend adult prisons
adopt many of the same models and tools, such as men-
torship programmes and comprehensive screens like the
CHAT, which are used in youth offending institutions.
Support upon prison release
Prison release and the transition into civilian life is a
period of increased vulnerability requiring offenders with
ADHD to receive specific timely support. There is a
need for further research on ways to best support of-
fenders with ADHD who are released from prison;
meanwhile we recommend implementing a critical time
intervention approach [60], in which a designated person
meets with the offender just before and immediately
after release from prison to help implement their care
plan and ensure subsequent engagement in healthcare.
Appropriate support would include: connecting the of-
fender with their care plan coordinator, ensuring regis-
tration with a primary care physician, and helping them
understand the implications of discontinuing treatment.
Because uninterrupted treatment with ADHD medica-
tion is vitally important, we further emphasize the need
to implement a medication management plan.
Discussion
There is strong evidence of a high prevalence of of-
fenders (both youth and adults, males and females) with
ADHD in prison and who have increased risk of associ-
ated coexisting conditions and higher rates of recidivism.
Paired with the evidence that treatment improves
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symptoms and outcomes, accurate identification and
comprehensive treatment is warranted. Effective inter-
vention is expected to have a positive impact on the of-
fender and society and lead to increased productivity,
decreased resource utilization, and most importantly re-
duced rates of re-offending.
The United Kingdom ADHD Partnership therefore
hosted a meeting of experts on the topic who reviewed
the literature and shared personal experiences. It was
concluded that there were specific barriers within the
prison that hindered the recognition of offenders within
the system with ADHD. These include inadequate staff
and offender awareness of ADHD symptoms and treat-
ments; lack of training for mental health staff; inappro-
priate use of screening and diagnostic tools;
inappropriate multimodal interventions, care manage-
ment, supportive services, and multiagency liaison; and a
lack of preparation for prison release to address the on-
going needs and care of prisoners with ADHD.
We successfully came to a consensus on practical ways
to address these problems and it was clear that the work
needs to commence with recognition and identification,
and this will involve training. To appropriately care for
the individual needs of each offender we recognize that
a separate pathway for each mental health disorder
(including ADHD) would need to be created. Realizing
this may be a problem, we therefore aim to influence
criminal justice systems to create a unifying mental
health approach with different interventions that address
each disorder. We envision a fully integrated interven-
tion pathway—in which the information gathered from
screenings and assessments is automatically shared with
appropriate service departments for the immediate and
coordinated implementation of necessary interventions.
The increased use of the CHAT screening tool, the
launch of healthcare standards and commissioning guid-
ance, and the development and implementation of the
SECURE STAIRS (an integrated framework of care
funded by the NHSE) together are supporting a unifying
mental health approach within the secure estate for chil-
dren and young people in England. Additionally, the
NHSE’s report The Five Year Forward View for Mental
Health [61] outlines general recommendations to sup-
port all offenders in the criminal justice system who are
experiencing mental health problems. The report recom-
mends expanding liaison and diversion schemes nation-
ally and urges the establishment of comprehensive
pathways and quality standards. We advise increasing
the use of the B-BAARS [33, 35] as a screening tool to
support the identification of adult offenders with ADHD.
Our approach based upon expert consensus is directly
aligned with these current efforts and offers practical so-
lutions to address the un-met needs of offenders with
ADHD.
The outcome of the review and consensus is detailed
above and the key conclusions and recommendations
that arose from it are briefly summarised in Table 1.
While a practical approach to effectively identify
and treat offenders with ADHD was achieved at the
meeting, it was clear that future research is needed to
identify optimal clinical operating models and moni-
tor their implementation and measure their success.
It will be valuable to investigate the impact of accur-
ate identification and specifically targeted multimodal
treatments on offender health, behaviour, and offence
related outcomes. Further research on the needs of
female offenders is needed.
Table 1 Recommendations
Identification and Assessment
1. Prison staff training to develop awareness of ADHD symptoms and
co-morbid conditions (including how these may differ by age and
gender), treatments, expected outcomes and the potential impact
of prison regime on the offender with ADHD (e.g. greater risk of
suicide, impact of segregation). This should include recognition
that many offender mental health issues are secondary to ADHD.
2. For youths, adoption of a suitable primary screen (e.g. CHAT) and a
clinical diagnostic interview (e.g. ACE). If a rating scale is
given (e.g. SNAP-IV, CBRS) this should be sensitive to both
inattention and hyperactivity/impulsivity symptoms.
3. For adults, adoption of a suitable primary screen (e.g. B-BAARS)
and a clinical diagnostic interview (e.g. ACE+, CAADID, DIVA-2).
If a rating scale is given (e.g. BAARS) this should be sensitive to
both inattention and hyperactivity/impulsivity symptoms.
Interventions and Treatment
4. All treatments should include psychoeducation about ADHD,
including symptoms, co-morbidity, pharmacological and non-
pharmacological treatments, side-effects of treatment and expected
outcomes.
5. Adoption of appropriate pharmacological and non-pharmacological
treatments (see Fig. 1).
6. Adoption of appropriate educational and occupational
programmes designed to increase engagement (see Fig. 1).
7. Educational and occupational programmes should be prioritised
that advance vocational, creative, technical, and/or athletic skills.
Care Management and Multiagency Liaison
8. There should be close liaison between education and mental
health services within the criminal justice system
9. A care plan coordinator should be assigned to the offender while
in prison.
10. A comprehensive care plan should be established, including a
medication management plan, for the offender while in prison
(see Additional file 1, online supplementary material).
11. The care plan should also plan to prepare the offender with
ADHD for release from prison (e.g. effecting a seamless transition
to ensure continuity of care and uninterrupted treatment with
ADHD medication; arranging appropriate links with supportive
services and agencies).
12. A critical time intervention approach should be established for a
designated person to support the offender through the release
process, support implementation of the care plan and ensure
engagement in healthcare.
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A recent study investigating the economic consequences
of ADHD in prison has conservatively estimated that the
financial burdon of medical and behaviour-related prison
care is £11.7 million per annum [62] and future research
should evaluate the financial benefits to society of effect-
ively treating offenders with ADHD (compared with
not-treating) using functional related outcomes. It will be
essential to demonstrate the cost effectiveness of interven-
tion using health economic modelling techniques to gar-
ner governmental support and effect change in criminal
justice and mental health service policies.
Conclusion
This consensus will inform effective identification and
treatment of offenders with ADHD. Appropriate interven-
tion is expected to have a positive impact on the offender
and society and may lead to increased productivity, de-
creased resource utilization, and most importantly re-
duced rates of re-offending.
Additional file
Additional file 1: Care Programme Approach (CPA) report. This is not
an actual CPA, but is a sample CPA report based on ‘real life’ cases.
(DOCX 12 kb)
Acknowledgements
We acknowledge the assistance of Luke Aldridge-Waddon, Emma-Louise
Bush, and Alexander Nolan who attended the consensus meeting and took
notes during the small group sessions. We also want to thank Dr. Jennifer
Kahle for attending the meeting and for assisting the note takers.
Funding
The meeting was funded by the UK ADHD partnership (UKAP). UKAP has
been supported with unrestricted donations from Shire. SY, BC, EF, JH, EW,
and GG are consultants with UKAP. None of the authors received funds for
attending the meeting or writing the manuscript, aside from KK who received
funds for developing the consensus statement.
Availability of data and materials
Not applicable.
Authors’ contributions
SY and GG led the planning and scientific input of this consensus statement.
All authors attended the consensus meeting. KK interpreted the meeting results
and wrote the first draft with input from SY and GG, subsequent drafts with
input from PA, and the final draft with input from all authors. All authors have
read and approved the final manuscript.
Authors’ information
Authors have the following expertise - Participation in UK Department of
Health initiatives (e.g. NICE Guidelines, NHS England Clinical Reference Group
for Offenders): SY, GG, AF, AL, PA. Past or current employment in ADHD
specialist clinical or educational services: SY, BC, EW, PA. Past or current
employment in general clinical services but with a special interest in ADHD:
GG, PC, EF, AF, JH, AL, SM, PM, SR, JS. Past or current service provision in
criminal justice services: SY, GG, PC, AF, JH, AL, SM, PM, EW, PA. ADHD
committee membership (e.g. UK Adult ADHD Network, ADHD Foundation,
ADHD Europe, European Network of Adult ADHD): SY, GG, BC, EF, JH, PM, JS,
EW, PA. Criminal justice committee membership (e.g. National Appropriate
Adult Network; expert evidence to a public account committee at the House
of Lords/House of Commons): GG, AF. Participation in Position Papers on
mental health and/or the criminal justice service for professional bodies
(e.g. British Psychological Society, Royal College of Psychiatry, World Psychiatric
Association Taskforce): SY, GG, AF, SM. KK is a medical writer who worked with
this group on a previous ADHD consensus statement.





SY has received honoraria for consultancy, sponsorship for attendance at
scientific meetings, educational talks, and/or research awards from Janssen,
Lilly, HB Pharma, and/or Shire. PM has received honoraria for consultancy
and lectures from Lilly, Shire, and Flynn Pharma. AL has received honoraria
for consultancy from Lilly. The remaining authors have no disclosures.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Psychology Services Limited, Croydon, UK. 2Institute of Psychiatry,
Psychology and Neuroscience, Department of Psychology, King’s College
London, London, UK. 3Offender Health Research Network, Division of
Psychology and Mental Health and Division of Medicine and Health,
University of Manchester, Manchester, UK. 4CLC Consultancy, Dunkeld,
Scotland, UK. 5Sussex Partnership NHS Foundation Trust, Children & Young
People’s Service, Tunbridge Wells Kent, UK. 6Forensic Psychiatry and Offender
Health Research Network, Division of Psychology and Mental Health and
Division of Medicine and Health, University of Manchester, Manchester, UK.
7Division of Psychology and Language Science, University College London,
London, UK. 8Independent Medical Writer, San Diego, California, USA. 9Barnet
Enfield & Haringey Mental Health NHS Trust, HMP/YOI Feltham, Feltham, UK.
10Health & Justice Central Team, NHS, London, UK. 11Kent Prisons, Oxleas
NHS Foundation Trust, Dartford, UK. 12Cheshire & Wirral Partnership NHS
Foundation Trust, The Stein Centre, St Catherine’s Hospital, Birkenhead, UK.
13Tees, Esk & Wear Valley NHS Foundation Trust, HMP Frankland, Durham, UK.
14Humber NHS Foundation Trust, East Yorkshire, London, UK. 15Institute of
Psychiatry, Psychology, and Neuroscience, Department of Forensic and
Neurodevelopmental Sciences, King’s College London, London, UK. 16South
London & Maudsley NHS Foundation Trust, National Adult Outpatient
Neurodevelopmental Clinic, and National Autism Unit, London, UK. 17Institute
of Psychiatry, Psychology, and Neuroscience, King’s College London, London,
UK.
Received: 20 July 2017 Accepted: 22 August 2018
References
1. Mohr-Jensen C, Steinhausen HC. A meta-analysis and systematic review of
the risks associated with childhood attention-deficit hyperactivity disorder
on long-term outcome of arrests, convictions, and incarcerations. Clin
Psychol Rev. 2016;48:32–42.
2. Young S, Wells J, Gudjonsson GH. Predictors of offending among prisoners:
the role of attention-deficit hyperactivity disorder and substance use. J
Psychopharmacol. 2011;25(11):1524–32.
3. Arnold LE, Hodgkins P, Caci H, Kahle J, Young S. Effect of treatment
modality on long-term outcomes in attention-deficit/hyperactivity disorder:
a systematic review. PLoS One. 2015;10(2):e0116407.
4. Young S, Gudjonsson GH, Goodwin EJ, Jotangia A, Farooq R, Haddrick D,
Adamou M. Beyond the gates: identifying and managing offenders with
attention deficit hyperactivity disorder in community probation services.
AIMS Public Health. 2014;1(1):33–42.
5. Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis
of attention-deficit/hyperactivity disorder in adult patients: a review of the
literature. Prim Care Companion CNS Disord. 2014;16(3):PCC.13r01600.
6. Young S, Adamou M, Bolea B, Gudjonsson GH, Müller U, Pitts M, Thome J,
Asherson P. The identification and management of ADHD offenders within
the criminal justice system: a consensus statement from the UK adult ADHD
network and criminal justice agencies. BMC Psychiatry. 2011;11(1):32.
Young et al. BMC Psychiatry  (2018) 18:281 Page 14 of 16
7. American Psychiatric Association. The diagnostic and statistical manual of
mental disorders. 5th ed. Arlington: VA; 2013.
8. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention
deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol
Med. 2006;36(2):159–65.
9. Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE. A systematic
review and analysis of long-term outcomes in attention deficit hyperactivity
disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99.
10. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide
prevalence of ADHD: a systematic review and metaregression analysis. Am J
Psychiatr. 2007;164(6):942–8.
11. Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates
of adult attention-deficit hyperactivity disorder: meta-analysis. Br J
Psychiatry. 2009;194(3):204–11.
12. Young S, Moss D, Sedgwick O, Fridman M, Hodgkins P. A meta-analysis of
the prevalence of attention deficit hyperactivity disorder in incarcerated
populations. Psychol Med. 2015;45(2):247–58.
13. Young S, Sedgwick O, Fridman M, Gudjonsson G, Hodgkins P, Lantigua M,
González RA. Co-morbid psychiatric disorders among incarcerated ADHD
populations: a meta-analysis. Psychol Med. 2015;45(12):2499–510.
14. Shaw J, Baker D, Hunt IM, Moloney A, Appleby L. Suicide by prisoners. Natl
Clin Surv. 2004;184(3):263–7.
15. Chang Z, Lichtenstein P, D'Onofrio BM, Sjolander A, Larsson H. Serious transport
accidents in adults with attention-deficit/hyperactivity disorder and the effect of
medication: a population-based study. JAMA Psychiatry. 2014;71(3):319–25.
16. Lichtenstein P, Larsson H. Medication for attention deficit-hyperactivity
disorder and criminality. N Engl J Med. 2013;368(8):776.
17. Chen Q, Sjolander A, Runeson B, D'Onofrio BM, Lichtenstein P, Larsson H.
Drug treatment for attention-deficit/hyperactivity disorder and suicidal
behaviour: register based study. BMJ. 2014;348:g3769.
18. Young S, Ross RR. R&R2 for ADHD youths and adults: A prosocial
competence training Program. Ottawa: Congitive Centre of Canada; 2007.
19. Young S, Emilsson B, Sigurdsson JF, Khondoker M, Philipp-Wiegmann F,
Baldursson G, Olafsdottir H, Gudjonsson GH. A randomized controlled trial
reporting functional outcomes of cognitive-behavioural therapy in
medication-treated adults with ADHD and comorbid psychopathology. Eur
Arch Psychiatry Clin Neurosci. 2017;267(3):267-76.
20. Young S, Khondoker M, Emilsson B, Sigurdsson JF, Philipp-Wiegmann F,
Baldursson G, Olafsdottir H, Gudjonsson GH. Cognitive–behavioural therapy
in medication-treated adults with attention-deficit/hyperactivity disorder
and co-morbid psychopathology: a randomized controlled trial using multi-
level analysis. Psychol Med. 2015;45(13):2793–804.
21. Emilsson B, Gudjonsson GH, Sigurdsson JF, Baldursson G, Einarsson E,
Olafsdottir H, Young S. Cognitive behaviour therapy in medication-treated
adults with ADHD and persistent symptoms: a randomized controlled trial.
BMC Psychiatry. 2011;11:116.
22. Chang Z, Lichtenstein P, Langstrom N, Larsson H, Fazel S. Association
between prescription of major psychotropic medications and violent
reoffending after prison release. Jama. 2016;316(17):1798–807.
23. Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S,
Langstrom N, Larsson H. Medication for attention deficit-hyperactivity
disorder and criminality. N Engl J Med. 2012;367(21):2006–14.
24. Walmsley R: World prison population list., 11th edn: world prison brief; 2015.
25. Martin MS, Colman I, Simpson AI, McKenzie K. Mental health screening tools
in correctional institutions: a systematic review. BMC Psychiatry. 2013;13:275.
26. Senior J, Birmingham L, Harty MA, Hassan L, Hayes AJ, Kendall K, King C,
Lathlean J, Lowthian C, Mills A, et al. Identification and management of
prisoners with severe psychiatric illness by specialist mental health services.
Psychol Med. 2013;43(7):1511–20.
27. Konstenius M, Larsson H, Lundholm L, Philips B, van de Glind G, Jayaram-Lindström
N, Franck J. An epidemiological study of ADHD, substance use, and comorbid
problems in incarcerated women in Sweden. J Atten Disord. 2012;19(1):44–52.
28. Hollingdale J, Woodhouse E, Asherson P, Gudjonsson GH, Young S. A pilot
study examining ADHD and Behavioural disturbance in female mentally
disordered offenders. AIMS Public Health. 2014;1(2):100–8.
29. Royal College of Paediatrics and Child Health. Healthcare standards for children
and young people in secure settings. London: Royal Collect of Paediatrics and
Child Health; 2013. https://www.rcpch.ac.uk/cypss. Accessed 29 Aug 2018.
30. Chitsabesan P, Lennox C, Theodosiou L, Law H, Bailey S, Shaw J. The
development of the comprehensive health assessment tool for young offenders
within the secure estate. J Forensic Psychiatry Psychol. 2014;25(1):1–25.
31. Bussing R, Fernandez M, Harwood M, Hou W, Garvan CW, Eyberg SM,
Swanson JM. Parent and teacher SNAP-IV ratings of attention deficit
hyperactivity disorder symptoms. Assessment. 2008;15(3):317–28.
32. Conners CK, Pitkanen J, Rzepa SR. Conners comprehensive behavior rating
scale. In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of Clinical
Neuropsychology. Edn. New York: Springer; 2011. p. 678–80.
33. ADHD Child Evaluation (ACE) [https://www.psychology-services.uk.com/
resources.htm]. Accessed 29 Aug 2018.
34. Kessler RC, Adler LA, Gruber MJ, Sarawate CA, Spencer T, Van Brunt DL.
Validity of the World Health Organization adult ADHD self-report scale
(ASRS) screener in a representative sample of health plan members. Int J
Methods Psychiatr Res. 2007;16(2):52–65.
35. Young S, González RA, Mutch L, Mallet-Lambert I, O'Rourke L, Hickey N,
Asherson P, Gudjonsson GH. Diagnostic accuracy of a brief screening tool
for attention deficit hyperactivity disorder in UK prison inmates. Psychol
Med. 2016;46(7):1449–58.
36. Brown K, Cullen A, Kooyman I, Forrester A. Mental health expertise at prison
reception. J Forensic Psychiatry Psychol. 2015;26(1):107–15.
37. Epstein JN, Johnson DE, Conners CK: CAADID: Conners adult ADHD
Diagnstic interview for DSM-IV: multi health systems (MHS); 2001.
38. Diagnosing ADHD in Adults: an examination of the discriminative validity of
neuropsychological tests and diagnostic assessment instruments. J Atten
Disord. 2018;22(11):1019-31.
39. Ramos-Quiroga JA, Nasillo V, Richarte V, Corrales M, Palma F, Ibáñez P,
Michelsen M, Van de Glind G, Casas M, Kooij JJS. Criteria and concurrent
validity of DIVA 2.0. J Atten Disord. 2016:1-10. https://doi.org/10.1177/
1087054716646451.
40. ACE+ [https://www.psychology-services.uk.com/resources.htm]. Accessed 29
Aug 2018.
41. UK Adult ADHD. Network: handbook for attention deficit hyperactivity
disorder in adults. London: UK: springer science & business media; 2013.
42. Naylor B. Human rights and their application in prisons , Monash University
Faculty of Law Legal Studies Research Paper No. Prison Serv J 2016. 2016;
9(227):17–22.
43. Forrester A, Piper, M, World psychiatric association: prison public health
position statement. 2017.
44. Metzner JL, Fellner J. Solitary confinement and mental illness in U.S. prisons:
a Challengefor medical ethics. J Am Acad Psychiatry Law. 2010;38(1):104–8.
45. Young S, Gudjonsson G, O'Rourke L, Woodhouse E, Ashwood K, Murphy D,
Asherson P. Attention-deficit-hyperactivity disorder and associated
functional impairments in mentally disordered offenders. Psychiatry Res.
2015;230(2):387–93.
46. Hughes N, Williams H, Chitsabesan P, Davies R, Mounce L. Nobody made
the connection: the prevalence of neurodisability in young people who
offend. London: The Office of the Children’s Commissioner; 2012.
47. Ginsberg Y, Lindefors N. Methylphenidate treatment of adult male prison
inmates with attention-deficit hyperactivity disorder: randomised double-
blind placebo-controlled trial with open-label extension. Br J Psychiatry.
2012;200(1):68–73.
48. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of
methylphenidate in the treatment of ADHD. Am J Psychiatr. 2003;160(11):1909–18.
49. Attention deficit hyperactivity disorder Diagnosis and management of ADHD
in children, young people and adults. NICE Clinical Guideline 72; 2009.
50. Young S, González R, Wolff K, Xenitidis K, Mutch L, Mallet-Lambert I,
Gudjonsson GH. Transitions and motivations for substance misuse in prison
inmates with ADHD and conduct disorder: validation of a new instrument. J
Dual Diagn. (in press)
51. Young S, González R, Wolff K, Xenitidis K, Mutch LM-LI, Gudjonsson GH.
Substance and alcohol misuse, drug pathways and offending behaviours in
association with ADHD in prison inmates. J Atten Disord. (in press)
52. King S, Gieve M. Evaluation of a pilot to deliver forensic mental health
interventions to young people at risk of violent offending. Commissioned
by MOPAC. London: The Tavistock Institute; 2013.
53. Solanto MV, Marks DJ, Wasserstein J, Mitchell K, Abikoff H, Alvir JM, Kofman
MD. Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatr.
2010;167(8):958–68.
54. Philipsen A, Graf E, Jans T, Matthies S, Borel P, Colla M, Gentschow L,
Langner D, Jacob C, Gross-Lesch S, et al. A randomized controlled
multicenter trial on the multimodal treatment of adult attention-deficit
hyperactivity disorder: enrollment and characteristics of the study sample.
Atten Deficit Hyperact disord. 2014;6(1):35–47.
Young et al. BMC Psychiatry  (2018) 18:281 Page 15 of 16
55. Young S, Bramham J. Cognitive-behavioural therapy for ADHD in
adolescents and adults: A Psychological Guide to Practice. 2nd ed.
Chichester: Wiley.; 2012.
56. Barry TD, Lyman RD, Klinger LG. Academic underachievement and
attention-deficit/hyperactivity disorder: the negative impact of symptom
severity on school performance. J Sch Psychol. 2002;40(3):259–83.
57. Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D,
Marrs A, Ouellette C, Moore P, et al. A prospective 4-year follow-up study of
attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry.
1996;53(5):437–46.
58. Care Programme Approach [http://www.nhs.uk/Conditions/social-care-and-
support-guide/Pages/care-programme-approach.aspx]. Accessed 29 Aug
2018.
59. Attention deficit hyperactivity disorder: Diagnosis and management: NICE
guideline [NG87]. 2018. https://www.nice.org.uk/guidance/ng87. Accessed
29 Aug 2018.
60. Jarrett M, Thornicroft G, Forrester A, Harty M, Senior J, King C, Huckle S,
Parrott J, Dunn G, Shaw J. Continuity of care for recently released prisoners
with mental illness: a pilot randomised controlled trial testing the feasibility
of a critical time intervention. Epidemiol Psychiatr Sci. 2012;21(2):187–93.
61. National Health Service England. The five year forward view for mental
health. Mental Health Taskforce Strategy. 2016:1–81. https://www.england.
nhs.uk/mental-health/taskforce/. Accessed 29 Aug 2018.
62. Young S, Gonzalez R, Fridman M, Hodgkins P, Kim K, Gudjonsson G. The
economic consequences of ADHD in the Scottish prison system. BMC
Psychiatry. 18:210. https://doi.org/10.1186/s12888-018-1792-x.
Young et al. BMC Psychiatry  (2018) 18:281 Page 16 of 16
